AIM
TVRD

Advantage Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

Advantage Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1K Hold
1
– – ﹤0.01% 901
2019
Q2 		$1K Hold
1
– – ﹤0.01% 920
2019
Q1 		$1K Hold
1
– – ﹤0.01% 911
2018
Q4 		$0 Hold
1
– – ﹤0.01% 1097
2018
Q3 		$1K Hold
1
– – ﹤0.01% 992
2018
Q2 		$1K Hold
1
– – ﹤0.01% 932
2018
Q1 		$0 Hold
1
– – ﹤0.01% 1077
2017
Q4 		$0 Hold
1
– – ﹤0.01% 1092
2017
Q3 		$0 Hold
1
– – ﹤0.01% 1132
2017
Q2 		$0 Hold
1
– – ﹤0.01% 1127
2017
Q1 		$1K Hold
1
– – ﹤0.01% 955
2016
Q4 		$0 Hold
1
– – ﹤0.01% 1028
2016
Q3 		$0 Buy
+1
New +$217 ﹤0.01% 974

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Advantage Investment Management's TVRD Position: Q3 2019 in Review

Advantage Investment Management held its Tvardi Therapeutics (TVRD) position steady in Q3 2019 at 1 share worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #901.

Advantage Investment Management first reported a position in TVRD in Q3 2016 and has held it in 13 quarters since. 144 funds tracked by Wall St. Rank hold TVRD as of Q3 2019.

  • Advantage Investment Management held 1 share of Tvardi Therapeutics worth $1K as of Q3 2019.
  • Advantage Investment Management left its Tvardi Therapeutics share count unchanged in Q3 2019.
  • Tvardi Therapeutics made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #901 holding.
  • Advantage Investment Management first reported a position in Tvardi Therapeutics in Q3 2016 and has held it in 13 quarters since.
  • 144 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.